Raul Fernandez-Prado, Priscila Villalvazo, Alejandro Avello, Marina Gonzalez-de-Rivera, Michelle Aguirre, Carlos G Carrasco-Muñoz, Beatriz Fernandez-Fernandez, Catalina Martin-Cleary, Sol Carriazo, Maria Dolores Sanchez-Niño, Maria Vanessa Perez-Gomez, Alberto Ortiz
Metabolic acidosis is frequent in chronic kidney disease (CKD) and is associated with accelerated progression of CKD, hypercatabolism, bone disease, hyperkalemia, and mortality. Clinical guidelines recommend a target serum bicarbonate ≥ 22 mmol/L, but metabolic acidosis frequently remains undiagnosed and untreated. Sodium zirconium cyclosilicate (SZC) binds potassium in the gut and is approved to treat hyperkalemia. In clinical trials with a primary endpoint of serum potassium, SZC increased serum bicarbonate, thus treating CKD-associated metabolic acidosis...
February 2023: Biomedicine & Pharmacotherapy